Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2019-10-22 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Morepen Laboratories Ltd has informed BSE regarding Issuance of Duplicate Share Certificates of the Company.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about informing the exchanges about duplicate share certificates issued to shareholders, listing folio numbers, old and new certificate numbers, and shareholder names. There is no financial data, no report or presentation, no voting results, no management or board changes, no earnings or audit information. This is a regulatory announcement related to share certificates, which does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is not a report publication announcement since it is not announcing a report release. The best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2019-10-22 English
Please find enclosed herewith Certificate pursuant to Regulation 40 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Filings Classification · 95% confidence The document is a certificate issued by a practicing company secretary pursuant to Regulation 40 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the half-year ended 30th September 2019. It certifies the timely issuance of share certificates related to transfers and other share-related activities. The document is a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is also not an announcement of a report but a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and certification documents.
2019-10-21 English
Morepen Laboratories Ltd has informed BSE regarding Loss of Share Certificates of the Company.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the loss of share certificates and the request for issuance of duplicate share certificates. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The content is an official notification about a shareholder's lost share certificates and the procedural update to the exchanges. It does not contain financial statements, management discussion, earnings data, or any report publication. It is not a report itself but an announcement related to shareholding records. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-10-16 English
Morepen Laboratories Ltd has informed BSE regarding Loss of Share Certificates of the Company.
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the loss of share certificates by shareholders and the request for issuance of duplicate share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 39(3). The content is about notifying the stock exchanges of lost share certificates and related administrative details. There is no financial data, no report attached or referenced as being published, no management discussion, no earnings or audit information, and no mention of voting or capital changes. This type of document is a regulatory announcement related to compliance and shareholder record-keeping, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-10-15 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release from Morepen Laboratories Limited announcing the addition of three new drugs to its API portfolio. It includes detailed information about the drugs, market sizes, patent expirations, and company plans for commercial launch and R&D investment. There are no financial statements, regulatory filings, or meeting materials. The content is clearly a corporate announcement about product portfolio expansion and commercial strategy, typical of a press release or capital/financing update. It is not an earnings release, annual report, or any other regulatory filing. Given the nature of the announcement about new products and commercial launch plans, the most appropriate classification is Capital/Financing Update (CAP).
2019-10-14 English
Press Release with the title ''Morepen Labs adds three new drugs - Rivaroxaban, Vildagliptin and UDCA to its API portfolio.''
Capital/Financing Update Classification · 95% confidence The document is a press release from Morepen Laboratories Limited announcing the addition of three new drugs to its API portfolio. It includes detailed information about the drugs, market sizes, patent expirations, and company plans for commercial launch and R&D investment. There are no financial statements, regulatory filings, or meeting materials. The content is clearly a press release announcing a product and business update, not an earnings release or financial report. Therefore, the document fits best under the category of Capital/Financing Update (CAP) as it relates to business expansion and product portfolio enhancement, which is typical for CAP filings. The document length and detail also support this classification rather than a brief announcement or regulatory filing.
2019-10-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.